Semi-Permanent Mass Production of Ac-225 for Cancer Therapy by the (3n,x) Reaction in Pressurized Water Reactor

Alpha particle-emitting radiopharmaceuticals are in high demand for use in targeted alpha therapy. Ac-225 is currently produced using Th-229, but its annual production remains low, approximately 63 GBq. Previously, we produced a large amount of Ac-225 via the (n,2n) reaction in fast reactors; however, it required repetitive irradiation. In this work, we investigated a method to produce Th-229 via the (3n,x) reaction through long-term irradiation using neutrons from Pressurized Water Reactors. As target nuclides, Ra-226, which is commonly used for Ac-225 production, and Th-230, which is not widely used but is abundant, were selected. The evaluation was conducted under mixed conditions of Th-230 and Th-232. Ra-226 and Th-230 produce Th-229 (T1/2 = 7920 years) after long-term neutron irradiation. Th-229, which has a long half-life, the alpha-decays to produce Ra-225, and the beta-decays of Ra-225 to produce Ac-225. These processes are semi-permanent owing to the long half-life of Th-229. Further, an irradiation method that does not require major changes in the upper part of the PWR fuel assembly geometry was employed by replacing the plugging device attached to the control rod guide tube with a target pin. The PWR loaded with abundant natural thorium target and irradiated with thermal neutrons for as long as approximately 5 years can produce more than twice the current world supply of Ac-225 annually and permanently.